Muscular Disorders, Atrophic
14
2
3
7
Key Insights
Highlights
Success Rate
88% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 17/100
7.1%
1 terminated out of 14 trials
87.5%
+1.0% vs benchmark
29%
4 trials in Phase 3/4
57%
4 of 7 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 7 completed trials
Clinical Trials (14)
Managed Access Program for Del-zota in Participants With DMD Mutations Amenable to Exon 44 Skipping
Interfacing With NeuroTechnology to Expand Neural Throughput (INTENT)
Long-Term Outcomes of Ataluren in Duchenne Muscular Dystrophy
Dietary Strategy to Tackle Cognitive and Locomotor Abilities in Early Elderly Subjects
A Study of Deramiocel (CAP-1002) in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy
Extension of AOC 1001-CS1 (MARINA) Study in Adult Myotonic Dystrophy Type 1 (DM1) Patients
A Study of CAP-1002 in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy
Molecular Mechanisms Underlying Anabolic Resistance to Protein Intake During Muscle Disuse
What Are the Effects of Lower Limb Dysmetria on Gluteus Medius and Erector Spinae Musculature?
Bruxism and Underlying Psichological Factors
Absorption, Metabolism, Excretion and Absolute Bioavailability of EDG-5506 in Healthy Volunteers
An Extension Study of Ataluren (PTC124) in Participants With Nonsense Mutation Dystrophinopathy
Phase 3 Study of Ataluren in Participants With Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD)
Diagnostic Accuracy of MR in Myositis